Can a Lab-Grown artery graft outlast current options?

NCT ID NCT07733076

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new biological graft, LineMatrix®, for replacing or bypassing damaged arteries in the lower body. About 15 adults with peripheral artery disease or other artery damage will receive the graft during surgery. Researchers will track how well the graft stays open without additional procedures over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a biological vascular graft called LineMatrix® used to replace or bypass damaged arteries
What this could lead to: If successful, this graft could offer a more durable option for artery repair, reducing the need for repeat surgeries.
What could go wrong: This is a very small, early study with only 15 participants, so results may not apply widely. Risks include graft blockage, infection, or failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.